NO990595L - Anvendelse av chelateringsmiddelet clikinol ved fremstilling av en farmas°ytisk sammensetning for behandling av alzheimers sykdom - Google Patents

Anvendelse av chelateringsmiddelet clikinol ved fremstilling av en farmas°ytisk sammensetning for behandling av alzheimers sykdom

Info

Publication number
NO990595L
NO990595L NO990595A NO990595A NO990595L NO 990595 L NO990595 L NO 990595L NO 990595 A NO990595 A NO 990595A NO 990595 A NO990595 A NO 990595A NO 990595 L NO990595 L NO 990595L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
clikinol
alzheimer
disease
preparation
Prior art date
Application number
NO990595A
Other languages
English (en)
Other versions
NO316768B1 (no
NO990595D0 (no
Inventor
Panayotis Nikolas Gerolymatos
Original Assignee
P N Gerolymatos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by P N Gerolymatos Sa filed Critical P N Gerolymatos Sa
Publication of NO990595D0 publication Critical patent/NO990595D0/no
Publication of NO316768B1 publication Critical patent/NO316768B1/no
Publication of NO990595L publication Critical patent/NO990595L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO990595A 1996-08-13 1999-02-09 Anvendelse av chelateringsmiddelet clikinol ved fremstilling av en farmas°ytisk sammensetning for behandling av alzheimers sykdom NO990595L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR96100286 1996-08-13
PCT/IB1997/000983 WO1998006403A1 (en) 1996-08-13 1997-08-08 Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
NO990595D0 NO990595D0 (no) 1999-02-09
NO316768B1 NO316768B1 (no) 1999-04-12
NO990595L true NO990595L (no) 1999-04-12

Family

ID=10942479

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990595A NO990595L (no) 1996-08-13 1999-02-09 Anvendelse av chelateringsmiddelet clikinol ved fremstilling av en farmas°ytisk sammensetning for behandling av alzheimers sykdom

Country Status (26)

Country Link
US (1) US6001852A (no)
EP (1) EP0959888B1 (no)
JP (1) JP2000516606A (no)
KR (1) KR100489969B1 (no)
CN (1) CN1114407C (no)
AT (1) ATE205086T1 (no)
AU (1) AU720643B2 (no)
BR (1) BR9711194A (no)
CA (1) CA2264097C (no)
CZ (2) CZ292411B6 (no)
DE (1) DE69706566T2 (no)
DK (1) DK0959888T3 (no)
ES (1) ES2162319T3 (no)
HK (1) HK1022437A1 (no)
HU (1) HUP9903906A3 (no)
IL (1) IL128416A (no)
IS (1) IS1907B (no)
NO (1) NO990595L (no)
NZ (1) NZ334124A (no)
PL (1) PL188838B1 (no)
PT (1) PT959888E (no)
RU (1) RU2193406C2 (no)
SI (1) SI0959888T1 (no)
SK (1) SK283117B6 (no)
TR (1) TR199900293T2 (no)
WO (1) WO1998006403A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
CA2301706C (en) 1997-08-21 2005-10-04 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
EP1032403B1 (en) * 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
TR200101892T2 (tr) * 1999-01-07 2001-11-21 P.N. Gerolymatos S.A. Hafıza bozukluklarının tedavisi veya önlenmesi için fankuinonun kullanımı.
US6692234B2 (en) 1999-03-22 2004-02-17 Water Management Systems Pump system with vacuum source
CN1422269A (zh) * 2000-02-09 2003-06-04 北陆制药株式会社 1h－咪唑并吡啶衍生物
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
US6803379B2 (en) * 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
WO2004031161A1 (en) 2002-10-04 2004-04-15 Prana Biotechnology Limited Neurologically-active compounds
US20080063599A1 (en) * 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
WO2004087160A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
US20070275943A1 (en) * 2003-11-19 2007-11-29 Acrux Dds Pty Ltd. Method and Composition for Treatment or Prophylaxis of Amyloidosis Disorders
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
AU2005227420B2 (en) * 2005-10-14 2013-05-09 Alltech, Inc. Method and compositions for altering cell function
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
CN101432302A (zh) * 2005-11-30 2009-05-13 艾博特公司 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
WO2007118276A1 (en) * 2006-04-14 2007-10-25 Prana Biotechnology Ltd Method of treatment of age-related macular degeneration(amd)
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
TW201815827A (zh) * 2006-07-14 2018-05-01 瑞士商Ａｃ免疫公司 抗β-類澱粉抗體或其抗原結合片段、其用途及使用方法
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
ES2332687B1 (es) * 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
FR2966827B1 (fr) 2010-10-27 2014-08-22 Kimonella Ventures Ltd Compose peptidique utile pour l'inhibition de la formation de plaques amyloides
KR101802048B1 (ko) * 2013-04-02 2017-12-28 안지 파마슈티컬 코퍼레이션 리미티드 항신경퇴행성제로서의 다작용성 퀴놀린 유도체
US11844774B2 (en) 2014-04-24 2023-12-19 Omoidesouzou Co., Ltd. Amyloid fiber formation limiter or inhibitor
KR20160057500A (ko) * 2014-11-05 2016-05-24 아카데미아 시니카 클리오퀴놀을 포함하는 자폐증 스펙트럼 장애의 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174899A (en) * 1960-12-30 1965-03-23 Ciba Geigy Corp Composition for the management of post antibiotic enteritis
US3178343A (en) * 1962-11-27 1965-04-13 Ciba Geigy Corp Pharmaceutical compositions and method of using same
DE1617417A1 (de) * 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
DE3932338A1 (de) * 1989-09-28 1991-04-11 Nmi Naturwissenschaftl U Mediz Verfahren zur praeventiven therapie von morbus alzheimer
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
GB9108080D0 (en) * 1991-04-15 1991-06-05 Smithkline Beecham Plc Pharmaceutical composition
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
JP3277211B2 (ja) * 1991-11-12 2002-04-22 プラナ・バイオテクノロジー・リミテッド アルツハイマー病の試験方法と治療方法
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
AU1831195A (en) * 1994-01-13 1995-08-01 Research Foundation For Mental Hygiene, Inc. Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
AU6580494A (en) * 1994-05-11 1995-12-05 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including (h. pylori), infections and related diseases
US5505958A (en) * 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture

Also Published As

Publication number Publication date
ES2162319T3 (es) 2001-12-16
NO316768B1 (no) 1999-04-12
CN1114407C (zh) 2003-07-16
IS4972A (is) 1999-02-10
PT959888E (pt) 2002-02-28
IL128416A0 (en) 2000-01-31
CN1230115A (zh) 1999-09-29
DK0959888T3 (da) 2001-11-05
AU720643B2 (en) 2000-06-08
SK283117B6 (sk) 2003-02-04
CZ295118B6 (cs) 2005-05-18
DE69706566T2 (de) 2002-07-11
HUP9903906A3 (en) 2001-01-29
ATE205086T1 (de) 2001-09-15
HUP9903906A2 (hu) 2000-04-28
EP0959888B1 (en) 2001-09-05
NO990595D0 (no) 1999-02-09
HK1022437A1 (en) 2000-08-11
JP2000516606A (ja) 2000-12-12
EP0959888A1 (en) 1999-12-01
CZ48499A3 (cs) 1999-07-14
RU2193406C2 (ru) 2002-11-27
NZ334124A (en) 2000-10-27
SI0959888T1 (en) 2002-10-31
BR9711194A (pt) 2000-01-11
KR100489969B1 (ko) 2005-05-17
WO1998006403A1 (en) 1998-02-19
TR199900293T2 (xx) 1999-06-21
IS1907B (is) 2003-12-16
PL188838B1 (pl) 2005-04-29
SK17999A3 (en) 1999-09-10
PL331822A1 (en) 1999-08-02
DE69706566D1 (de) 2001-10-11
CZ292411B6 (cs) 2003-09-17
AU3632497A (en) 1998-03-06
KR20000029958A (ko) 2000-05-25
US6001852A (en) 1999-12-14
CA2264097A1 (en) 1998-02-19
CA2264097C (en) 2007-11-27
IL128416A (en) 2004-06-01

Similar Documents

Publication Publication Date Title
NO990595L (no) Anvendelse av chelateringsmiddelet clikinol ved fremstilling av en farmas°ytisk sammensetning for behandling av alzheimers sykdom
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
EP0793660A4 (en) 2-SUBSTITUTED 1,2,5-THIADIAZOLIDIN-3-ON-1,1-DIOXIDES, COMPOSITION AND THEIR USE
GB9103764D0 (en) Compositions
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
BG106151A (en) Pharmaceutical complex
NO990450L (no) Behandling av sinnslidelser
AU2002215187A1 (en) S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
GEP20002141B (en) Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease
IT1263076B (it) Uso orale e topico della n-acetil-5-metossitriptamina (melatonina) nella terapia della psoriasi volgare.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application